- Global Blood Therapeutics ended 2020 with a nearly 40% drop in its share price.
- The pandemic negatively affected the number of Oxbryta prescriptions and therefore Oxbryta sales.
- Despite the setback due to the pandemic, Oxbryta's sales potential remains immense, at several billion dollars.
- We should begin to see a significant increase in Oxbryta's sales in the coming quarters, once the pandemic begins to subside in the United States thanks to mass vaccinations of the population.
For further details see:
Global Blood Therapeutics: Ready To Face A Promising Year In 2021